These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 5881987)

  • 1. [Pharmacokinetics of sulfamethopyrazine in man. 1st experiences with minimum dosages].
    Boschi F; Clini V; Gialdroni-Grassi G
    G Ital Chemioter; 1965; 12(1):67-73. PubMed ID: 5881987
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of a specific neutrophil elastase inhibitor (ONO-5046) in pulmonary ischemia-reperfusion injury.
    Ishikawa N; Oda M; Kawaguchi M; Tsunezuka Y; Watanabe G
    Transpl Int; 2003 May; 16(5):341-6. PubMed ID: 12759726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method of determining in man protein-binding and antimicrobial activity of long-acting sulfonamides.
    Tauber LF; Batterman RC; Bell ME
    Proc West Pharmacol Soc; 1965; 8():67. PubMed ID: 5863054
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sodium sulfapyridazine treatment of infectious inflammatory affections of respiratory organs].
    Ashbel' SI; Bogoslovskaia IA; Guseva EA; Sokolova VG; Khil' RG
    Sov Med; 1966 Nov; 29(11):32-6. PubMed ID: 6004473
    [No Abstract]   [Full Text] [Related]  

  • 5. [Physicochemical and biological studies on sulfonamides. 2. Protein-binding, pharmacokinetics and distribution of 5 sulfonamides in rabbits].
    RIEDER J
    Arzneimittelforschung; 1963 Feb; 13():89-95. PubMed ID: 13982262
    [No Abstract]   [Full Text] [Related]  

  • 6. [Meaning of binding sulfamines to plasma proteins].
    Berlin H
    Rev Bras Gastroenterol; 1967; 19(4):19-23. PubMed ID: 5595387
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical experiences in parenteral treatment with a broncho-secretolytic agent].
    Marquardt R
    Med Monatsschr; 1966 Jul; 20(7):322-4. PubMed ID: 5927494
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sulfonamides and the multiplication of yeast parasites in man].
    Ansel M; Thibaut M
    Therapie; 1967; 22(4):919-25. PubMed ID: 6062710
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experiences with the new mucolytic agent Bisolvon in general practice, with special reference to asthmoid states].
    Stäubli C
    Praxis; 1966 Jul; 55(30):850-3. PubMed ID: 5953646
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical experiences with cefoperazone. A new cephalosporine derivative for pulmonary infections].
    Liener A
    Med Welt; 1982 Feb; 33(5):188-90. PubMed ID: 6461813
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic processes influencing the pharmacokinetics of sulfonamides.
    Büttner H; Portwich F
    Antimicrob Agents Chemother (Bethesda); 1965; 5():177-9. PubMed ID: 5883422
    [No Abstract]   [Full Text] [Related]  

  • 12. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the clinical use of a sulfonamide (sulfamethopyrazine) according to the new trends in dosage].
    Scalvini A; Delmonte A
    Minerva Med; 1967 Dec; 58(100):4584-95. PubMed ID: 6081722
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experiences with & observations on hypoglycemic sulfonamides. IV. Determination of liver function & blood proteins].
    TOPI GC; ALESSANDRINI A; JACOBELLI A; FORCINA G
    Prog Med (Napoli); 1957 Aug; 13(15):451-8. PubMed ID: 13485197
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of corticoids in acute lung diseases and long-lasting lung diseases].
    Philit F
    Rev Pneumol Clin; 1998 Sep; 54 Suppl 2():S7-8. PubMed ID: 9769957
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic uses of a new sulfonamide: sulfamethopyrazine].
    HOVHANNESSIAN-FAUVE L
    Gaz Med Fr; 1960 Jul; 67():1677-80. PubMed ID: 13716198
    [No Abstract]   [Full Text] [Related]  

  • 18. [On pharmacokinetics of rectal application, demonstrated on example of 4-sulfanilamido-5,6-dimethoxy-pyrimidine. 2. Experimental part].
    Diller W; Bünger P
    Arzneimittelforschung; 1965 Dec; 15(12):1445-56. PubMed ID: 5899819
    [No Abstract]   [Full Text] [Related]  

  • 19. [Binding of some sulfanilamides to blood proteins of man. 1. Determinations of low sulfanilamide concentrations in vitro at room temperature].
    Spring P
    Arzneimittelforschung; 1966 Mar; 16(3):346-54. PubMed ID: 6013844
    [No Abstract]   [Full Text] [Related]  

  • 20. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.
    Armstrong HE; Galka A; Lin LS; Lanza TJ; Jewell JP; Shah SK; Guthikonda R; Truong Q; Chang LL; Quaker G; Colandrea VJ; Tong X; Wang J; Xu S; Fong TM; Shen CP; Lao J; Chen J; Shearman LP; Stribling DS; Rosko K; Strack A; Ha S; Van der Ploeg L; Goulet MT; Hagmann WK
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2184-7. PubMed ID: 17293109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.